Syapse, a Palo Alto, California-based provider of precision medicine software, completed the first close of a $25m Series C funding round.
The round is being led by Ascension Ventures, a subsidiary of Ascension, the nation’s largest non-profit and Catholic health system, with participation from existing investors Social Capital Partnership and Safeguard Scientifics (NYSE:SFE).
The company intends to use the funds to expansion adoption of its software in community health systems.
Led by Glenn Winokur, CEO, Syapse provides academic and community health systems with a cloud-based software to support widespread adoption of precision medicine in oncology. The software was built to enable four key processes:
– Integrating clinical, genomic, and other molecular data from medical records, labs, and pharmacies to see the full longitudinal profile of a patient
– Providing guidance on the appropriate diagnostic and therapeutic strategy, based on clinical best practices
– Implementing treatment decisions more effectively, and coordinating complex care across large, geographically dispersed care teams, and
– Measuring patient outcomes to learn what works and improve best practices.